ALXN News and Press, Alexion Pharmaceuticals Inc. From 03/18/21

Full phase 3 data for Apellis Pharmaceuticals' (APLS) paroxysmal nocturnal hemoglobinuria (PNH) drug candidate pegcetacoplan indicates it is superior to Alexion Pharmaceuticals' (ALXN) Soliris (eculizumab).The data was published in The New England Journal of Medicine.Full results from the PEG...

A day after the U.S. Federal Trade Commission signaled more scrutiny over what was considered as ‘anti-competitive’ mergers in the pharmaceutical industry, Citi analysts have weighed in on its impact on big pharma’s growth ambitions.The analysts Andrew Baum and ...

The U.S. Federal Trade Commission announced today that it's staring a working group to update its approach to analyzing the effects of pharmaceutical mergers.“Given the high volume of pharmaceutical mergers in recent years, amid skyrocketing drug prices and ongoing concerns about antic...

AstraZeneca (AZN) has refiled its planned takeover of Alexion (ALXN) with U.S. antitrust regulators, according to an 8-K fling.Following informal talks with Federal Trade Commission, AZN told the FTC that it would withdraw its notification and refile it on or around March 16. It originally fi...

– Data highlight long-term and real-world efficacy of SOLIRIS ® (eculizumab) in patients living with rare neurologic complement-mediated disorders, including neuromyelitis optica spectrum disorder (NMOSD) and generalized myasthenia gravis (gMG) – Ale...

John Paulson’s 13F portfolio value increased from $3.21B to $3.85B this quarter. Paulson & Company's largest three positions are Horizon Therapeutics, Bausch Health, and BrightSphere Investment Group. The stake in Barrick Gold was more than doubled during the quarter. ...

Merger activity decreased last week with four new deals announced. The acquisition of Enable Midstream Partners by Energy Transfer. The acquisition of Tribune Publishing Company by Alden Golden Capital. For further details see: Merger Arbitrage Mondays - Consolidati...

Orladeyo now has regulatory approval for sale in the USA and Japan. The Oral Factor D Phase 1 data is due to be published in the 1st quarter. BioCryst announced $325 Million of funding from Royalty Pharma and Athyrium Capital Management. Baker Brothers and Sarrisa Capital now ...

Apellis Pharmaceuticals is gearing up for potential approval of its PNH drug pegcetacoplan; the PDUFA date has been established for May 14, 2021. Pegcetacoplan achieved superior increase in hemoglobin levels in a head to heady study against Soliris. Upon FDA approval, pegcetacoplan ma...

Form 13F filings show fund managers' top arbitrage stocks. Top M&A stocks of the 31 funds I follow. Only two of the top 10 are cash deals. For further details see: Top Merger Stocks Held By Fund Managers, Mid-Q1 2021